Diabetes Care, Vol 21, Issue 11 1997-2002, Copyright © 1998 by American Diabetes Association

ARTICLES

The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes

TJ Berg, JT Clausen, PA Torjesen, K Dahl-Jorgensen, HJ Bangstad and KF Hanssen
Aker Diabetes Research Center, Aker University Hospital, Oslo, Norway. t.j.berg@ioks.uio.no

OBJECTIVE: To investigate whether children and adolescents with type 1 diabetes have increased serum levels of the glycoxidation product Nepsilon-(carboxymethyl)lysine (CML) at an early stage of the disease. RESEARCH DESIGN AND METHODS: The serum levels of CML in 38 patients with type 1 diabetes aged 14+/-3.2 (mean+/-SD) years were compared with those in 26 control subjects aged 16+/-1.7 years. The mean duration of diabetes was 5+/-4.7 years, ranging from 0.5 to 15 years. The mean levels of HbA1c were 10.3+/-2.5% in the patient group. The serum levels of CML were measured using a monoclonal anti-CML antibody in a fluoremetric immunoassay. Serum protein levels of advanced glycation end products (AGEs) were assayed using a polyclonal antibody from rabbit immunized with AGE-RNase (pAGE). RESULTS: The serum levels of CML and pAGE were significantly increased in the patient group versus the control group: 1.08 (0.45-2.97) U/ml CML (median 10-90 percentiles) vs. 0.70 (0.36-1.79) U/ml CML, P < 0.03, and 6.6 (5.1-9.9) U/ml pAGE vs. 5.5 (3.7-8.2) U/ml AGEs, P < 0.01. A significant relationship between CML and pAGE was found in the IDDM group, r = 0.76, P < 0.001. The CML levels were not associated with the HbAlc levels (n = 23, r = -0.02, NS), cholesterol levels (n = 21, r = 0.07, NS), age, sex, or diabetes duration. CONCLUSIONS: Serum levels of CML are increased in patients with type 1 diabetes. This increase precedes the development of micro- and macrovascular complications.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Facchiano, D. D'Arcangelo, K. Russo, V. Fogliano, C. Mennella, R. Ragone, G. Zambruno, V. Carbone, D. Ribatti, C. Peschle, et al. Glycated Fibroblast Growth Factor-2 Is Quickly Produced in Vitro upon Low-Millimolar Glucose Treatment and Detected in Vivo in Diabetic Mice Mol. Endocrinol., November 1, 2006; 20(11): 2806 - 2818. [Abstract] [Full Text] [PDF]

				A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]

				B. K. Kilhovd, A. Juutilainen, S. Lehto, T. Ronnemaa, P. A. Torjesen, K. I. Birkeland, T. J. Berg, K. F. Hanssen, and M. Laakso High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men: A Population-Based 18-Year Follow-Up Study Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 815 - 820. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				A. Galler, G. Muller, R. Schinzel, J. Kratzsch, W. Kiess, and G. Munch Impact of Metabolic Control and Serum Lipids on the Concentration of Advanced Glycation End Products in the Serum of Children and Adolescents With Type 1 Diabetes, as Determined by Fluorescence Spectroscopy and N{epsilon}-(Carboxymethyl)Lysine ELISA Diabetes Care, September 1, 2003; 26(9): 2609 - 2615. [Abstract] [Full Text] [PDF]

				R. D. G. Leslie, H. Beyan, P. Sawtell, B. O. Boehm, T. D. Spector, and H. Snieder Level of an Advanced Glycated End Product Is Genetically Determined: A Study of Normal Twins Diabetes, September 1, 2003; 52(9): 2441 - 2444. [Abstract] [Full Text] [PDF]

				R. B. Santana, L. Xu, H. B. Chase, S. Amar, D. T. Graves, and P. C. Trackman A Role for Advanced Glycation End Products in Diminished Bone Healing in Type 1 Diabetes Diabetes, June 1, 2003; 52(6): 1502 - 1510. [Abstract] [Full Text] [PDF]

				F. Facchiano, A. Lentini, V. Fogliano, S. Mancarella, C. Rossi, A. Facchiano, and M. C. Capogrossi Sugar-Induced Modification of Fibroblast Growth Factor 2 Reduces Its Angiogenic Activity in Vivo Am. J. Pathol., August 1, 2002; 161(2): 531 - 541. [Abstract] [Full Text] [PDF]

				A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P. M. Humpert, J. Chen, M. Hong, T. Luther, T. Henle, I. Kloting, et al. Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-{kappa}B Diabetes, December 1, 2001; 50(12): 2792 - 2808. [Abstract] [Full Text] [PDF]

				T. Uchimura, K. Nakano, T. Hashiguchi, H. Iwamoto, K. Miura, Y. Yoshimura, N. Hanyu, K. Hirata, M. Imakuma, Y. Motomiya, et al. Elevation of N-(Carboxymethyl)valine Residue in Hemoglobin of Diabetic Patients: Its role in the development of diabetic nephropathy Diabetes Care, May 1, 2001; 24(5): 891 - 896. [Abstract] [Full Text]

				T. Kislinger, C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan, M. Hofmann, S. F. Yan, M. Pischetsrieder, D. Stern, et al. Nepsilon -(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression J. Biol. Chem., October 29, 1999; 274(44): 31740 - 31749. [Abstract] [Full Text] [PDF]